01/31/2018

PREVIOUS POST
Nmp 22 - A New Marker Of Malignant Tumors For Cancer Diagnosis NMP 22 - a new marker for the diagnosis of malignant tumors of bladder cancer. Bladder cancer - is the "silent cancer, which can be from 10 to 20 years without symptoms and complaints in the human body, and suddenly, for unknown medical science reasons to begin to develop. Therefore, special types of early diagnosis is crucial for early treatment and preservation of life. The presence of blood (hematuria) in the urine is the most common syndrome of primary bladder tumors. Painless hematuria than occurs - blood in urine, even if it takes place only once, the more likely is the presence of cancer. The most common bladder cancer occurs in smokers, those who have long been at the wheel, of Light and chemical industries, people are in constant contact with paints and chemicals, as well as in patients who take a long time painkillers. Cancer-causing substances can be absorbed through the skin or the air that people breathe, and excreted in the urine. Chronic inflammation of the bladder and urinary disturbance and contribute to the development of bladder cancer. For timely diagnosis of bladder cancer now using a new recently developed a urine test - NMP22. Nuclear Matrix Protein 22 - nuclear protein, which themselves generate the cancer cells. Diagnosis of NMP 22 can detect bladder cancer at an early stage. Russian Institute for International Patients Health Munich (www.meditravel-plus.com) to appreciate the latest treatments for urinary incontinence in men and women who are satisfied with the treatment and its results. Diagnosis of bladder cancer NMP22 allowed in a number of clinical able to detect cases of cancer and the spread of cancer cells throughout the body. Dr. Victor Kramer, chief medical adviser of the International Institute of Health in Munich, Germany

Recent Comments